Every US Ebola patient received experimental product, official says

Amid a grilling about what went wrong in Dallas, calls for travel bans from West Africa, including restrictions for dogs) and fears that Ebola could become airborne, one statement may have been buried in Thursday’s congressional hearing on the U.S. Ebola response.

mashable tweet
Luciana Borio, assistant commissioner for counterterrorism policy at the U.S. Food and Drug Administration, didn’t receive the same volume of questioning or level of scrutiny as Tom Frieden, director of the Centers for Disease Control and Prevention (and the public face of the U.S.’ response to Ebola).

But in her testimony, she said something we may not have known before—and that wasn’t included in her published remarks: “Every Ebola patient in the U.S. has been treated with at least one investigational product.”

Getty Images Director of the Office of Counterterrorism and Emerging Threats in the U.S. Food and Drug Administration's Office of the Chief Scientist Luciana Borio

Getty Images
Director of the Office of Counterterrorism and Emerging Threats in the U.S. Food and Drug Administration’s Office of the Chief Scientist Luciana Borio

Now, whether this definitely means each Ebola patient under treatment has received a drug is likely, but unclear— “investigational products” could potentially mean other things, and the FDA won’t clarify. But if she was referring to drugs, that means three patients—an unnamed person being treated at Emory University Hospital, who was flown back from West Africa, and Dallas nurses Nina Pham and Amber Vinson—are receiving therapies that hadn’t yet been disclosed.

Read More No Ebola epidemic in US without ‘mutation:’ CDC

We know that Kent Brantly and Nancy Writebol, the first Americans to be flown back from West Africa for treatment in the U.S., received the experimental drug ZMapp, from Mapp Biopharma. And it eventually emerged that Rick Sacra, who was treated in Nebraska, got Tekmira‘s experimental medicine, TKM-Ebola. All recovered.

We also know that Thomas Eric Duncan, the Liberian man who was the first person to be diagnosed with Ebola on U.S. soil, and Ashoka Mukpo, the NBC cameraman flown back to Nebraska for treatment, received Chimerix‘s experimental antiviral drug brincidofovir. Mukpo is said to be recovering; Duncan passed away Oct. 8.

Read More Why we haven’t cured Ebola yet

It’s important to remember that none of these drugs were used in controlled clinical trial settings for Ebola, and it’s difficult to take anything away about their efficacy, or lack thereof, from these circumstances. Each patient had a unique experience, also received supportive care and in some cases, received donated blood from Ebola survivors.

So too, will the experiences of the three other patients, whose treatment hasn’t been disclosed, be unique.

The patient being treated at Emory, who was admitted in early September and about whom few details are known, released a statement Wednesday.

“Given the national focus on Ebola, particularly with the diagnosis in two health-care workers, I want to share the news that I am recovering from this disease, and that I anticipate being discharged very soon, free from the Ebola virus and able to return safely to my family and to my community,” the anonymous patient said. “As a result of the virus, my condition worsened and I became critically ill soon after I arrived at Emory. Through rigorous medical treatment, skillful nursing and the full support of a health-care team, I am well on the way to a full recovery.”

Read More UN: Ebola fund only has $100,000 in bank

Vinson, who was diagnosed Wednesday, was transferred from Dallas to Emory later the same day for treatment. If she’s receiving an experimental drug, the treatment decision was made swiftly. Pham, who was diagnosed Sunday, was moved Thursday to a treatment center at the National Institutes of Health.

CDC’s Frieden has said treatment decisions, including experimental drugs, are up to the patients, their families and their physicians.

Similarly to the first group of patients, few conclusions can be drawn from knowing these patients may be receiving experimental therapy. Of course, that doesn’t stop the market from reacting to news.

This entry was posted in Biotech & Pharmaceuticals, Health Care. Bookmark the permalink.

Leave a Reply